Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg

Heidelberg 69126

4 studies enrolling now · 18 studies all time

What they study most

Bronchiectasis, Extensive-stage Small Cell Lung Cancer (ES-SCLC), Idiopathic Pulmonary Fibrosis, Interstitial Lung Diseases, Lung Cancer, Non-squamous, Non-small Cell, Lung Diseases, Interstitial, Mesothelioma, Non-small Cell Lung Cancer, Progressive Pulmonary Fibrosis, Scleroderma, Systemic, Small Cell Lung Cancer (SCLC), Small Cell Lung Carcinoma (SCLC)

Studies at this site

• A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast — Recruiting now
• DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy — Recruiting now
• The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis — Recruiting now
• Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations — Recruiting now
• FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression — Starting soon
• DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy — Running, not enrolling
• Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment — Running, not enrolling
• A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis — Stopped early
• A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) — Completed
• A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) — Completed
• A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis — Completed
• Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment — Completed
• A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) — Completed
• A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) — Completed
• Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) — Completed
• A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis — Completed
• Nintedanib (BIBF 1120) in Mesothelioma — Stopped early
• Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF — Completed